Role of co-expression of c-Myc, EZH2 and p27 in prognosis of prostate cancer patients after surgery

Chinese Medical Journal

Volumn 126, Issue 1, 2013, Pages 82-87

  Li, Ke ^a   Chen, Ming Kun ^a   Situ, Jie ^a   Huang, Wen Tao ^a   Su, Zu Lan ^a   He, Dan ^a   Gao, Xin ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Biochemical recurrence; C Myc; EZH2; P27; Prognosis; Prostate cancer

Indexed keywords

MYC PROTEIN; PROTEIN P27; TRANSCRIPTION FACTOR EZH2;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PROSTATE CANCER; PROTEIN EXPRESSION;

CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYCOMB REPRESSIVE COMPLEX 2; PROGNOSIS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84874396449     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20122477     Document Type: Article

References (29)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nonogran for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766-771.
3. Chen WZ, Pang B, Yang B, Zhou JG, Sun YH. Differential proteome analysis of conditioned medium of BPH-1 and LNCaP cells. Chin Med J 2011; 124: 3806-3809.
4. Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, et al. Overexpression of C-MYC oncogene in prostate cancer predicts BCR. Prostate Cancer Prostatic Dis 2010; 13: 311-315.
5. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T. EZH2, Ki-129 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008; 122: 595-602
6. Thomas GV, Schrage MI, Rosenfelt L, Kim JH, Salur G, deKernion JB, et al. Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J Urol 2000; 164: 1987-1991.
7. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200.
8. Hoedemaeker RRE, Ruizeveld de Winter JA, Van der Kaa CA, van der Kwast TH. Processing radical prostatectomy specimens. A comprehensive and standardized protocol. J Urol Pathol 1998; 9: 211-222.
9. Nikoleishvili D, Pertia A, Trsintsadze O, Gogokhia N, Managadze L, Chkhotua A. Expression of p27 (Kip1), cyclin D3 and Ki129 in BPH, prostate cancer and hormone-treated prostate cancer cells. Int Urol Nephrol 2008; 40: 953-959.
10. van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007; 52: 455-463.
11. Yang G, Timme TL, Frolov A, Wheeler TM, Thompson TC. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 2005; 103: 1186-1194.
12. Yuan JQ, Xu T, Zhang XW, Yu LP, Li Q, Liu SJ, et al. Metabolic syndrome and androgen deprivation therapy in metabolic complications of prostate cancer patients. Chin Med J 2012; 125: 3725-3729.
13. Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev 2009; 35: 9-17.
14. Xia SJ, Jing YF. Biochemical recurrence of prostate cancer: the controversial recognition and management. Chin Med J 2011; 124: 1283-1285.
15. D'Amico AV, Desjardin A, Chung A, Chen MH. Assessment of outcome prediction models for localized prostate cancer in patients managed with external beam radiation therapy. Semin Urol Oncol 1998; 16: 153-159.
16. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, et al. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J 2012; 18: 1-8.
17. Nguyen PL, Chen MH, Beard CJ, Suh WW, Renshaw AA, Loffredo M, et al. Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a post-randomization analysis by risk group. Int J Radiat Oncol Biol Phys 2010; 77: 1046-1052.
18. Koh CM, Bieberich CJ, Dang CV, Nelson WG, Yegnasubramanian S, De Marzo AM. MYC and prostate cancer. Genes Cancer 2010; 1: 617-628.
19. Gorrini C, Donzelli M, Torriglia A, Supino R, Brison O, Bernardi R, et al. Effect of apoptogenic stimuli on colon carcinoma cell lines with a different c-myc expression level. Int J Mol Med 2003; 11: 737-742.
20. Ellwood-Yen K, Graeber TG, Wongvipat J, Iruela-Arispe ML, Zhang J, Matusik R, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003; 4: 223-238.
21. Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, et al. MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood 2008; 112: 4202-12.
22. Saramäki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 2006; 45: 639-645.
23. Bryant RJ, Cross NA, Eaton CL, Hamdy FC, Cunliffe VT. EZH2 promotes proliferation and invasiveness of prostate cancer cells. Prostate 2007; 129: 547-556.
24. Guo SQ, Zhang YZ. Overexpression of enhancer of zests homolog 2 in lymphoma. Chin Med J 2012; 125: 3735-3739.
25. MacLachlan TK, Sang N, Giordano A. Cyclins, cyclin-dpendent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit Rev Eukaryot Gene Expr 1995; 5: 127-156.
26. Dvorácková J, Uvírová M. A molecularly genetic determination of prognostic factors of the prostate cancer and their relationships to expression of protein p27kip1. Neoplasma 2007; 54: 149-154.
27. Fussbroich B, Wagener N, Macher-Goeppinger S, Benner A, Fälth M, Sültmann H, et al. EZH2 depletion blocks the proliferation of colon cancer cells. PLoS One 2011; 6: e21651: 1-14.
28. Malhotra S, Lapointe J, Salari K, Higgins JP, Ferrari M, Montgomery K, et al. A tri-marker proliferation index predicts biochemical recurrence after surgery for prostate cancer. PLoS One 2011; 6: e20293: 1-8.
29. Land H, Parada LF, Weinberg RA. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 1983; 304: 596-602.